Norges Bank Travere Therapeutics, Inc. Transaction History

Norges Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $373,460 - $587,880	71,000 New	71,000 $583,000
Q4 2023 Feb 09, 2024	BUY	$5.44 - $9.5 $386,240 - $674,500	71,000 New	71,000 $638,000
Q3 2023 Nov 13, 2024	BUY	$7.64 - $17.25 $542,440 - $1.22 Million	71,000 New	71,000 $634,000
Q3 2023 Nov 13, 2023	SELL	$7.64 - $17.25 $1.8 Million - $4.07 Million	-235,900 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $1.41 Million - $2.08 Million	-91,900 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$17.82 - $22.89 $1.27 Million - $1.63 Million	71,000 New	71,000 $1.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $3.97 Million - $5.62 Million	215,000 New	215,000 $4.52 Million
Q3 2022 Nov 13, 2023	BUY	$22.91 - $28.63 $5.4 Million - $6.75 Million	235,900 New	235,900 $5.81 Million
Q2 2022 Aug 14, 2023	BUY	$20.94 - $30.01 $1.92 Million - $2.76 Million	91,900 New	91,900 $2.23 Million
Q1 2021 May 07, 2021	SELL	$23.37 - $31.77 $577,005 - $784,401	-24,690 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$19.17 - $27.87 $473,307 - $688,110	24,690 New	24,690 $673,000

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.